KalVista Pharmaceuticals Spearheads Breakthrough Research at 2024 Bradykinin Symposium in Berlin’
CAMBRIDGE, Mass. & SALISBURY, England ’ Setting a notable milestone in its research trajectory, KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is preparing for a prominent role at the 2024 Bradykinin Symposium in Berlin, Germany. The company has announced the acceptance of six abstracts for presentation, a testament to its pioneering work in the field of hereditary angioedema (HAE) and other bradykinin-mediated disorders. This significant conference will be held from September 5-6, 2024, in the distinguished Kaiserin Friedrich-Haus Lecture Hall.
On Friday, September 6, KalVista’s research team will unveil its latest findings through a series of oral presentations, addressing critical gaps and innovative solutions in the treatment of HAE. One of the most anticipated presentations is led by Mauro Canci
Comments